VISION
For liver health to take its place on the global public health agenda commensurate with its prevalence and impact.
MISSION
To improve the effectiveness of the liver community by promoting innovation, collaboriation, and scaling optimal approaches to eradicating liver disease.
The Global Liver Institute (GLI) serves the liver community by:
1. Increasing the voice for liver issues in the global public health conversation
2. Facilitating collaborative approaches and knowledge–sharing among patient advocates, policymakers, regulators, public health officials, clinicians and researchers in liver disease and therapeutic areas related to liver disease (e.g. HIV, IBD, cancer)
3. Attracting and highlighting innovation, particularly digital/technical innovation, to challenges faced by liver patients
OUR VALUES
Patient-Centric
We empower individuals with liver disease, and those who care for them, to be full partners in defeating liver disease.
Collaborative
We believe that more can be accomplished by working together. We actively seek partnerships with other organizations in liver disease, HIV, oncology, diabetes, obesity, and other relevant stakeholders previously not engaged with the community.
Inclusive
We include diverse populations, geographies, racial/ethnic groups, socio-economic status, and all forms of liver disease in our approach to governance, programming, and communications.
Bold
We work to proactively identify, collect, share, and aggressively promote best practices to scale, as well as attract and accelerate innovation.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close